Wagar shares thoughts on phenotype testing for endometrial cancer with OncLive

Matt Wagar, MD, a gynecologic oncologic fellow in the Division of Gynecologic Oncology, spoke with OncLive for a recent story about endometrial cancer and potential treatments and tests for it.

In “Dr. Wagar on the Use of T-DXd in Patients With HER2+ Endometrial Cancer,” Wagar recommended that healthcare providers testing or working with endometrial cancer should use HER2 testing is early as possible, and explained how HER2 positivity used gastric cancer criteria, which is different from uterine cancer standards.

“I would [advise colleagues] to always think about requesting HER2 testing from the get-go for patients with endometrial cancer. If you’re concerned [that a patient might] have an aggressive phenotype and worried about their response to systemic therapy, having that information ahead of time [could allow you to quickly] switch [therapies based on a patient’s treatment] trajectory,” said Wagar.

Read the full article here.

**by Ob-Gyn Communications Intern Paige Stevenson